The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
JCI Insight · 22.06.2023 · 8 (12)
DOI: 10.1172/jci.insight.170671 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 22.06.2023. Verfasst von Vicky Chuong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intr…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Alcoholism. Die Arbeit wurde bisher 218-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, Intramural NIH HHS, NIH.
Abstract (Originalsprache)
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD). Here, we examined the effects of semaglutide, a long-acting GLP-1 analogue, on biobehavioral correlates of alcohol use in rodents. A drinking-in-the-dark procedure was used to test the effects of semaglutide on binge-like drinking in male and female mice. We also tested the effects of semaglutide on binge-like and dependence-induced alcohol drinking in male and female rats, as well as acute effects of semaglutide on spontaneous inhibitory postsynaptic currents (sIPSCs) from central amygdala (CeA) and infralimbic cortex (ILC) neurons. Semaglutide dose-dependently reduced binge-like alcohol drinking in mice; a similar effect was observed on the intake of other caloric/noncaloric solutions. Semaglutide also reduced binge-like and dependence-induced alcohol drinking in rats. Semaglutide increased sIPSC frequency in CeA and ILC neurons from alcohol-naive rats, suggesting enhanced GABA release, but had no overall effect on GABA transmission in alcohol-dependent rats. In conclusion, the GLP-1 analogue semaglutide decreased alcohol intake across different drinking models and species and modulated central GABA neurotransmission, providing support for clinical testing of semaglutide as a potentially novel pharmacotherapy for AUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program (NIDA IRP) and National Institute on Alcohol A…
- Neurobiology of Addiction Section, NIDA IRP, NIH, Baltimore, Maryland, USA.
- Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, USA.
- Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
- Stress and Addiction Neuroscience Unit, NIDA IRP and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland, USA.
Förderung
- NIAAA NIH HHS
- Intramural NIH HHS
- NIH
Zitieren
APA
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C., Koob, G. F., Roberto, M., Vendruscolo, L. F., & Leggio, L. (2023). The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight, 8(12). https://doi.org/10.1172/jci.insight.170671
Vancouver
Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8(12). doi:10.1172/jci.insight.170671
BibTeX
@article{Chuong2023,
author = {Chuong, Vicky and Farokhnia, Mehdi and Khom, Sophia and Pince, Claire L and Elvig, Sophie K and Vlkolinsky, Roman and Marchette, Renata Cn and Koob, George F and Roberto, Marisa and Vendruscolo, Leandro F and Leggio, Lorenzo},
title = {The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission},
journal = {JCI Insight},
year = {2023},
volume = {8},
number = {12},
doi = {10.1172/jci.insight.170671}
}
EUVIMED